Linked Life Data

9504783

Source:http://linkedlifedata.com/resource/pubmed/id/9504783

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9504783rdf:typepubmed:Citationlld:pubmed
pubmed-article:9504783lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:9504783lifeskim:mentionsumls-concept:C0002092lld:lifeskim
pubmed-article:9504783lifeskim:mentionsumls-concept:C0004096lld:lifeskim
pubmed-article:9504783lifeskim:mentionsumls-concept:C0021083lld:lifeskim
pubmed-article:9504783lifeskim:mentionsumls-concept:C0026231lld:lifeskim
pubmed-article:9504783lifeskim:mentionsumls-concept:C0085129lld:lifeskim
pubmed-article:9504783lifeskim:mentionsumls-concept:C0301630lld:lifeskim
pubmed-article:9504783lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:9504783pubmed:issue2lld:pubmed
pubmed-article:9504783pubmed:dateCreated1998-5-28lld:pubmed
pubmed-article:9504783pubmed:abstractTextEncasings for mattresses, blankets and pillows in combination with mite allergen reduction on the floor have proved effective in reducing bronchial hyperreactivity of mite-allergic children. We studied the effect of combining the use of encasings with specific immunotherapy in comparison to the use of encasings alone (control group). Twenty mite-allergic children (Skin Prick Test, RAST, mean age 10 years) with asthma and high domestic mite allergen exposure ( > 2 microg Der p 1 + f 1/g mattress dust) were included in our study. The concentration of these major allergens as well as specific and nonspecific bronchial hyperreactivity (PC20 FEV1 histamine) were assessed before, 6 months after and 1 year after start of treatment. All children received elongated polytetrafluorethylene (ePTFE; Goretex/Intervent Allergy Bedding System) encasings. A subgroup of eight children were treated additionally by specific immunotherapy with a partially purified mite extract (ALK Scherax) and a maximum dose of 100000 SQ-U Der p + f. Initially both groups were comparable with respect to the parameters assessed. In 80% of children, encasings reduced Der p 1 and Der f 1 concentrations on the mattress to below 3% of the initial values (P < 0.01). The median reduction was 99%. PC20 FEV1 histamine increased from 0.4 to 1.4 mg/dl (median) in the combined group with immunotherapy and encasings (P < 0.05) and remained essentially unchanged in the control group. PC20 FEV1 Der p did not increase significantly in either group. CONCLUSION: Specific immunotherapy with allergen extracts is an effective adjunct to encasings. Encasings, a key factor for reducing Der p 1 and Der f 1 on the mattress, should be used in combination with other avoidance measures (e.g. removal of carpets) in order to improve allergen-induced bronchial hyperreactivity.lld:pubmed
pubmed-article:9504783pubmed:languageenglld:pubmed
pubmed-article:9504783pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9504783pubmed:citationSubsetIMlld:pubmed
pubmed-article:9504783pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9504783pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9504783pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9504783pubmed:statusMEDLINElld:pubmed
pubmed-article:9504783pubmed:monthFeblld:pubmed
pubmed-article:9504783pubmed:issn0340-6199lld:pubmed
pubmed-article:9504783pubmed:authorpubmed-author:PaulKKlld:pubmed
pubmed-article:9504783pubmed:authorpubmed-author:WahnUUlld:pubmed
pubmed-article:9504783pubmed:authorpubmed-author:KlettkeUUlld:pubmed
pubmed-article:9504783pubmed:issnTypePrintlld:pubmed
pubmed-article:9504783pubmed:volume157lld:pubmed
pubmed-article:9504783pubmed:ownerNLMlld:pubmed
pubmed-article:9504783pubmed:authorsCompleteYlld:pubmed
pubmed-article:9504783pubmed:pagination109-13lld:pubmed
pubmed-article:9504783pubmed:dateRevised2006-4-19lld:pubmed
pubmed-article:9504783pubmed:meshHeadingpubmed-meshheading:9504783-...lld:pubmed
pubmed-article:9504783pubmed:meshHeadingpubmed-meshheading:9504783-...lld:pubmed
pubmed-article:9504783pubmed:meshHeadingpubmed-meshheading:9504783-...lld:pubmed
pubmed-article:9504783pubmed:meshHeadingpubmed-meshheading:9504783-...lld:pubmed
pubmed-article:9504783pubmed:meshHeadingpubmed-meshheading:9504783-...lld:pubmed
pubmed-article:9504783pubmed:meshHeadingpubmed-meshheading:9504783-...lld:pubmed
pubmed-article:9504783pubmed:meshHeadingpubmed-meshheading:9504783-...lld:pubmed
pubmed-article:9504783pubmed:meshHeadingpubmed-meshheading:9504783-...lld:pubmed
pubmed-article:9504783pubmed:meshHeadingpubmed-meshheading:9504783-...lld:pubmed
pubmed-article:9504783pubmed:meshHeadingpubmed-meshheading:9504783-...lld:pubmed
pubmed-article:9504783pubmed:meshHeadingpubmed-meshheading:9504783-...lld:pubmed
pubmed-article:9504783pubmed:meshHeadingpubmed-meshheading:9504783-...lld:pubmed
pubmed-article:9504783pubmed:meshHeadingpubmed-meshheading:9504783-...lld:pubmed
pubmed-article:9504783pubmed:meshHeadingpubmed-meshheading:9504783-...lld:pubmed
pubmed-article:9504783pubmed:meshHeadingpubmed-meshheading:9504783-...lld:pubmed
pubmed-article:9504783pubmed:meshHeadingpubmed-meshheading:9504783-...lld:pubmed
pubmed-article:9504783pubmed:meshHeadingpubmed-meshheading:9504783-...lld:pubmed
pubmed-article:9504783pubmed:meshHeadingpubmed-meshheading:9504783-...lld:pubmed
pubmed-article:9504783pubmed:meshHeadingpubmed-meshheading:9504783-...lld:pubmed
pubmed-article:9504783pubmed:year1998lld:pubmed
pubmed-article:9504783pubmed:articleTitleThe combined influence of immunotherapy and mite allergen reduction on bronchial hyperresponsiveness in mite-sensitive asthmatic children.lld:pubmed
pubmed-article:9504783pubmed:affiliationVirchow-Klinikum, Medizinische Fakultät der Humboldt-Universität zu Berlin, Pädiatrie m.S. Pneumologie/Immunologie, Germany.lld:pubmed
pubmed-article:9504783pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9504783lld:pubmed